Research presented this week at the European Society of Cardiology Congress in Munich suggests a new treatment may be emerging for transthyretin amyloid cardiomyopathy—a condition previously thought to be rare and untreatable.

Twice as many U.S. deaths due to cardiac amyloidosis were reported in 2015 than in 1979, but a study in JAMA Cardiology suggests the disease remains vastly underdiagnosed.

In the era of the Quadruple Aim, there’s no shortage of studies, media coverage and commentary on how our healthcare systems may be overusing resources.

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

Recent research found strain parameters taken from a cine MRI-based deformable registration algorithm (DRA) can determine the severity of amyloid buildup in the heart and may provide prognostic information on patients with light-chain (AL) amyloidosis.

While amyloid imaging is typically discussed with regard to diagnosing Alzheimer’s disease, a team of French researchers, presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 annual meeting, have found that amyloid scans of the heart can predict major cardiac events.

PET with 11C-PIB provides a noninvasive method for visualizing amyloid deposits in the heart, according to a study published in the February issue of the Journal of Nuclear Medicine. The researchers suggest that 11C-PIB eventually may be used in the clinical setting as both a diagnostic tool and a treatment follow-up method.